Pharmaceutical compound
Clinical data | |
---|---|
Other names | ACC-007, KM-023, Aibangde, Einovirine |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C18H19N3O3 |
Molar mass | 325.368 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Ainuovirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Kainos Medicine for the treatment of HIV infections. Ainuovirine was approved in China in 2021 for the treatment of HIV-1 infection.
References
- "Ainuovirine - Kainos Medicine". AdisInsight. Springer Nature Switzerland AG.
- Zhang Q, Chen Z, Wang Y, Peng Y, Tan S, Li Y, et al. (2023). "Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study". Frontiers in Medicine. 10: 1277059. doi:10.3389/fmed.2023.1277059. PMC 10800701. PMID 38259850.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |